At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 18, 2026 at 16:05 ET
Spero Therapeutics announced it will release its Q4 and full-year 2025 financial results on March 26, 2026, after market close. The company will not host a conference call, limiting immediate investor engagement and real-time clarification of results.
- Spero Therapeutics will report Q4 and full-year 2025 financial results on March 26, 2026, after market close.
- No conference call is planned, which may limit investor interaction and near-term market reaction.
- Company remains focused on clinical-stage development for rare and high unmet need diseases.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access